BIV 201

Drug Profile

BIV 201

Alternative Names: BIV201; Terlipressin acetate continuous infusion

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator BioVie
  • Class Antidiuretics; Antihaemorrhagics; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ascites
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ascites

Most Recent Events

  • 24 May 2017 BioVie receives patent allowance for BIV201 in USA
  • 25 Apr 2017 BioVie signs CRADA for the development of BIV 201 in Ascites
  • 03 Apr 2017 BioVie plans a phase IIa trial for Ascites (Treatment-experienced) in USA (IV) (NCT03107091)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top